SCHEMBL4076018

SCHEMBL4076018

CN(c1ccc2c(c1)OCO2)c1ncnc2cc(-c3cccc(C(F)(F)F)c3)sc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.43
CSF1R P07333 2/20 0.43
CLK4 Q9HAZ1 8/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 3/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2D6 P10635 3/20 0.41
CYP2C19 P33261 3/20 0.41
CYP3A4 P08684 2/20 0.41
TSHR P16473 2/20 0.41
MAPK1 P28482 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HIF1A Q16665 1/20 0.41
CLK1 P49759 7/20 0.40
CLK2 P49760 7/20 0.40
DYRK1A Q13627 7/20 0.40
DYRK1B Q9Y463 7/20 0.40
CLK3 P49761 5/20 0.40
FLT1 P17948 1/20 0.40
BRAF P15056 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933682 0.89 STK17B (0.44) EGFRCLK4ALDH1A1LMNACYP1A2
SCHEMBL4075049 0.87 MAP3K8 (0.45) EGFRCSF1RCLK4ALDH1A1LMNA
SCHEMBL4074719 0.87 EGFR (0.46) EGFRCLK4ALDH1A1LMNACYP1A2
SCHEMBL4069658 0.87 EGFR (0.47) EGFRCLK4ALDH1A1LMNACYP1A2
SCHEMBL4068214 0.87 CLK4 (0.42) EGFRCSF1RCLK4ALDH1A1LMNA
SCHEMBL4071470 0.85 CLK4 (0.45) EGFRCLK4ALDH1A1LMNACYP1A2
SCHEMBL4068416 0.85 TYK2 (0.49) EGFRCLK4ALDH1A1LMNACYP1A2
SCHEMBL3938276 0.85 CLK4 (0.51) EGFRCLK4ALDH1A1LMNACYP1A2
SCHEMBL3930205 0.85 CLK4 (0.45) EGFRCSF1RCLK4ALDH1A1LMNA
SCHEMBL4074807 0.85 STK17B (0.48) EGFRCLK4ALDH1A1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 EGFR 875/4885CSF1R 1260/4885CLK4 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.